S1PR1
Sphingosine 1-phosphate receptor 1
As of the edition of 20 October 2026, S1PR1 (sphingosine 1-phosphate receptor 1, UniProt P21453) has 11 drugs tested at it and 15 companies on the list, 3 on route A and 5 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P21453
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 21
- Disease areas
- Nervous system; Immune system; Digestive system; Skin and connective tissue; Cancer; Heart and blood vessels; Blood and lymph; Lungs and airways
- Registered trials of its drugs
- 230
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 5 |
| Active | 3 |
| Went quiet | 2 |
| Stopped | 1 |
| Total | 11 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Fingolimod | Marketed | Phase 4 | none listed |
| Ozanimod | Marketed | Phase 4 | Ends 2038 |
| Etrasimod | Marketed | Phase 4 | Ends 2036 |
| Ponesimod | Marketed | Phase 3 | Ends 2032 |
| Siponimod | Marketed | Phase 4 | Ends 2028 |
| Cenerimod | Active | Phase 3 | none listed |
| Amiselimod | Active | Phase 2 | none listed |
| Mocravimod | Active | Phase 3 | none listed |
| Tamuzimod | Stopped | Phase 2 | none listed |
| ASP-4058 | Went quiet | Phase 1 | none listed |
| SAR247799 | Went quiet | Phase 1 | none listed |
11 of 11 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 3 |
| Route B | 5 |
| Engaged | 5 |
| Undetermined | 2 |
| Total on the list | 15 |
| Company | Route |
|---|---|
| Bristol Myers Squibb | Route B |
| Pfizer | Route B |
| Mitsubishi Tanabe Pharma | Route B |
The other 12 companies at S1PR1
In the product15 companies in all; 12 are not named here, and no score is.
See the 15 companies at S1PR1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.